环氧化物水解酶2
促炎细胞因子
嗜酸性粒细胞趋化因子
支气管肺泡灌洗
卵清蛋白
炎症
免疫学
趋化因子
药理学
医学
嗜酸性粒细胞
肺
气道阻力
哮喘
化学
内科学
免疫系统
生物化学
酶
作者
Jun Yang,Jennifer M. Bratt,Lisa Franzi,Jun‐Yan Liu,Guodong Zhang,Amir A. Zeki,Christoph F. A. Vogel,Keisha Williams,Hua Dong,Yanping Lin,Sung Hee Hwang,Nicholas J. Kenyon,Bruce D. Hammock
标识
DOI:10.1165/rcmb.2013-0440oc
摘要
Control of airway inflammation is critical in asthma treatment. Soluble epoxide hydrolase (sEH) has recently been demonstrated as a novel therapeutic target for treating inflammation, including lung inflammation. We hypothesized that pharmacological inhibition of sEH can modulate the inflammatory response in a murine ovalbumin (OVA) model of asthma. BALB/c mice were sensitized and exposed to OVA over 6 weeks. A sEH inhibitor (sEHI) was administered for 2 weeks. Respiratory system compliance, resistance, and forced exhaled nitric oxide were measured. Lung lavage cell counts were performed, and selected cytokines and chemokines in the lung lavage fluid were measured. A LC/MS/MS method was used to measure 87 regulatory lipids mediators in plasma, lung tissue homogenates, and lung lavage fluid. The pharmacological inhibition of sEH increased concentrations of the antiinflammatory epoxy eicosatrienoic acids and simultaneously decreased the concentrations of the proinflammatory dihydroxyeicosatrienoic acids and dihydroxyoctadecenoic acids. All monitored inflammatory markers, including FeNO levels, and total cell and eosinophil numbers in the lung lavage of OVA-exposed mice were reduced by sEHI. The type 2 T helper cell (Th2) cytokines (IL-4, IL-5) and chemokines (Eotaxin and RANTES) were dramatically reduced after sEHI administration. Resistance and dynamic lung compliance were also improved by sEHI. We demonstrated that sEHI administration attenuates allergic airway inflammation and airway responsiveness in a murine model. sEHI may have potential as a novel therapeutic strategy for allergic asthma.
科研通智能强力驱动
Strongly Powered by AbleSci AI